The Biotech Basement Sale
April 10, 2026 The Biotech Basement Sale A $300 billion patent cliff, 46 FDA approvals in 2025, and a Q1…
Newsletters
Tesla’s Robotaxi Moment Is Here — But the Market Isn’t Buying It Yet
April 10, 2026 Tesla’s Robotaxi Moment Is Here — But the Market Isn’t Buying It Yet TSLA sits at a…
Apple’s Services Empire Is Quietly Repricing — Here’s What the Numbers Are Telling Traders
April 10, 2026 Apple’s Services Empire Is Quietly Repricing — Here’s What the Numbers Are Telling Traders With hardware growth…
Why the Market’s Favorite Bundle Is Breaking Apart in 2026
April 10, 2026 Why the Market’s Favorite Bundle Is Breaking Apart in 2026 The spread inside the Seven is now…
The “Double-Down” Diplomacy: When Geopolitics Cuts the Risk Premium
April 9, 2026 The “Double-Down” Diplomacy: When Geopolitics Cuts the Risk Premium A fear-driven dip met an unexpected catalyst: negotiations…
The AI CapEx Supercycle Is No Longer a Theory
April 9, 2026 The AI CapEx Supercycle Is No Longer a Theory Amazon’s $200B Commitment and Meta’s $21B CoreWeave Deal…
The AI CapEx Supercycle Is No Longer a Theory
April 9, 2026 The AI CapEx Supercycle Is No Longer a Theory Amazon’s $200B Commitment and Meta’s $21B CoreWeave Deal…
Energy Deflation: Oil’s 16% Faceplant and What the Market Is Really Pricing In
April 8, 2026 Energy Deflation: Oil’s 16% Faceplant and What the Market Is Really Pricing In WTI cratered to ~$94…
Meta’s Relief-Rally Jump: What the Market Heard in “Muse Spark”
April 8, 2026 Meta’s Relief-Rally Jump: What the Market Heard in “Muse Spark” A 6.5% move isn’t the story. The…
Healthcare Is Leading the Tape. Now Tell Me: Opportunity or Just Less Bad?
April 7, 2026 Healthcare Is Leading the Tape. Now Tell Me: Opportunity or Just Less Bad? CMS improved the Medicare…